

Includes Full-Text Download



CLINICAL DRUG DATA

11th Edition

Kelly M. Smith • Daniel M. Riche • Nickole N. Henyan

Clinical Drug Data

eleventh edition

EDITORS

Kelly M. Smith, PharmD, BCPS, FASHP, FCCP

Associate Dean, Academic and Student Affairs Practice
Associate Professor, Pharmacy Practice and Science
University of Kentucky College of Pharmacy
Lexington, Kentucky

Daniel M. Riche, PharmD, BCPS, CDE

Assistant Professor
University of Mississippi Schools of Pharmacy and Medicine
University of Mississippi Medical Center
Jackson, Mississippi

Nickole N. Henyan, PharmD

Clinical Pharmacist
Shore Health System
University of Maryland Medical System
Easton, Maryland




**GIFT OF THE ASIA FOUNDATION
NOT FOR RE-SALE**

**QUÀ TẶNG CỦA QUỸ CHÂU Á
KHÔNG ĐƯỢC BÁN LẠI**

**Mc
Graw
Hill**

Medical

New York Chicago San Francisco Lisbon London Madrid
Mexico City Milan New Delhi San Juan Seoul Singapore
Sydney Toronto



Clinical Drug Data, Eleventh Edition

Copyright © 2010 by The McGraw-Hill Companies, Inc. All rights reserved. Printed in the United States of America. Except as permitted under the United States Copyright Act of 1976, no part of this publication may be reproduced or distributed in any form or by any means, or stored in a data base or retrieval system, without the prior written permission of the publisher.

1 2 3 4 5 6 7 8 9 0 DOC/DOC 14 13 13 11 10

Set ISBN 978-0-07-162688-0; MHID 0-07-162688-0

Book ISBN 978-0-07-162685-9; MHID 0-07-162685-9

Bind-in-Card ISBN 978-0-07-162687-3; MHID 0-07-162687-5

This book was set in Times Roman at Aptara, Inc.

The editors were Michael Weitz and Regina Y. Brown.

The production supervisor was Sherri Souffrance.

Project management provided by Deepa Krishnan, Aptara, Inc.

The cover designer was Malvina D'Alterio.

RR Donnelley was printer and binder.

This book is printed on acid-free paper.

Cataloging-in-Publication is on file for this title at the Library of Congress.

International Edition Set ISBN 978-0-07-174845-2; MHID 0-07-174845-8

International Edition Book ISBN 978-0-07-174844-5; MHID 0-07-174844-X

International Bind-in-Card ISBN 978-0-07-162687-3; MHID 0-07-162687-5

Copyright © 2010. Exclusive rights by the McGraw-Hill Companies, Inc. for manufacture and export. This book cannot be re-exported from the country to which it is consigned by McGraw-Hill. The International Edition is not available in North America.

McGraw-Hill books are available at special quantity discounts to use as premiums and sales promotions, or for use in corporate training programs. To contact a representative please e-mail us at bulksales@mcgraw-hill.com.

Contents

<i>Contributors</i>	ix
<i>Preface</i>	xix
<i>How to Use This Book</i>	xxi

PART I DRUG MONOGRAPHS 1

Principal Editors: Daniel M. Riche and Nickole N. Henyan

Section 1	Analgesic and Anti-Inflammatory Drugs, Daniel M. Riche	3
Chapter 1	Antimigraine Drugs, Toy S. Biederman	3
Chapter 2	Antirheumatic Drugs, Danial E. Baker and Stephen M. Setter	12
Chapter 3	Chronic Gout Therapy, Daniel M. Riche	25
Chapter 4	Nonsteroidal Anti-Inflammatory Drugs, Stephen M. Setter and Danial E. Baker	35
Chapter 5	Opioids, Mark T. Holdsworth	52
Section 2	Antimicrobial Drugs, Daniel M. Riche	75
Chapter 6	Aminoglycosides, Renée-Claude Mercier	75
Chapter 7	Antifungal Drugs, John D. Cleary and Kayla R. Stover	83
Chapter 8	Antimycobacterial Drugs, Gina C. Biglane and Jessica H. Brady	111
Chapter 9	Antiparasitic Drugs, Kayla R. Stover	122
Chapter 10	Antiviral Drugs, David J. Caldwell	130
Chapter 11	β -Lactams, Christopher Betz and Courtney M. Brown	185
Chapter 12	Macrolides, Davey P. Legendre	223
Chapter 13	Quinolones, Mary Gauthier-Lewis and Treavor T. Riley	233
Chapter 14	Sulfonamides, Davey P. Legendre	242
Chapter 15	Tetracyclines, Roxie L. Stewart	246
Chapter 16	Hepatitis Antiviral Drugs, Julianna Chan	255
Chapter 17	Miscellaneous Antimicrobials, Mary Gauthier-Lewis and Treavor T. Riley	271

Section 3	Antineoplastics, Chemoprotectants, and Immunosuppressants, Nickole N. Henyan	289
Chapter 18	Antineoplastics, <i>Shirley Hogan</i>	289
Chapter 19	Alkylating Agents, <i>Shirley Hogan</i>	291
Chapter 20	Antimetabolites, <i>Shirley Hogan</i>	306
Chapter 21	Cytokines, <i>Shirley Hogan</i>	314
Chapter 22	DNA Intercalating Drugs, <i>Shirley Hogan</i>	317
Chapter 23	Hormonal Drugs and Antagonists, <i>Shirley Hogan</i>	322
Chapter 24	Mitotic Inhibitors, <i>Shirley Hogan</i>	330
Chapter 25	Monoclonal Antibodies, <i>Amber P. Lawson</i>	338
Chapter 26	Tyrosine Kinase Inhibitors, <i>Amber P. Lawson</i>	353
Chapter 27	Miscellaneous Antineoplastics, <i>Shirley Hogan</i>	369
Chapter 28	Chemoprotectants, <i>Shirley Hogan</i>	373
Chapter 29	Immunosuppressants, <i>Timothy M. Clifford</i>	376
Section 4	Cardiovascular Drugs, Nickole N. Henyan	395
Chapter 30	Antiarrhythmic Drugs, <i>Kurt Reinhart and C. Michael White</i>	395
Chapter 31	Antihypertensive Drugs, <i>James J. Nawarskas</i>	420
Chapter 32	β -Adrenergic Blocking Drugs, <i>Sachin A. Shah</i>	455
Chapter 33	Calcium Channel Blocking Drugs, <i>Sachin A. Shah</i>	463
Chapter 34	Hypolipidemic Drugs, <i>Daniel M. Riche and James M. Wooten</i>	471
Chapter 35	Inotropic and Vasopressor Drugs, <i>Robert J. DiDomenico</i>	494
Section 5	Central Nervous System, Daniel M. Riche	517
Chapter 36	Anticonvulsants, <i>April D. Miller</i>	517
Chapter 37	Antidepressants, <i>Aaron P. Gibson</i>	550
Chapter 38	Antipsychotic Drugs, <i>Aaron P. Gibson</i>	578
Chapter 39	Anxiolytics, Sedatives, and Hypnotics, <i>Aaron P. Gibson</i>	596
Chapter 40	Lithium, <i>Aaron P. Gibson</i>	611
Chapter 41	Neurodegenerative Disease Drugs, <i>Toy S. Biederman</i>	613
Chapter 42	Ophthalmic Drugs for Glaucoma, <i>Mikael D. Jones</i>	640
Section 6	Gastrointestinal Drugs, Daniel M. Riche	655
Chapter 43	Acid-Peptic Therapy, <i>P. Shane Winstead and George A. Davis</i>	655
Chapter 44	Antiemetics, <i>Mark T. Holdsworth</i>	677
Chapter 45	Gastrointestinal Motility and Miscellaneous Gastrointestinal Drugs, <i>Scott S. Malinowski</i>	695
Chapter 46	Inflammatory Bowel Disease, <i>Juliana Chan and John Garofalo</i>	717

Section 7	Hematologic Drugs, Nickole N. Henyan	729
Chapter 47	Coagulants and Anticoagulants, Krista D. Riche and Paula Horn	729
Chapter 48	Hematopoietics, Catherine E. Ferara	759
Section 8	Hormonal Drugs, Nickole N. Henyan	769
Chapter 49	Adrenal Hormones, Andrea N. Traina and Michael P. Kane	769
Chapter 50	Antidiabetic Drugs, Stephen M. Setter, John R. White Jr., and R. Keith Campbell	783
Chapter 51	Contraceptives, Peggy Piascik and T. Joseph Mattingly	806
Chapter 52	Female Sex Hormones, Peggy Piascik	826
Chapter 53	Thyroid and Antithyroid Drugs, Betty J. Dong	846
Section 9	Renal and Electrolytes, Daniel M. Riche	861
Chapter 54	Diuretics, Paul G. Cuddy	861
Chapter 55	Electrolytes, Paul G. Cuddy	882
Chapter 56	Bisphosphonates, Paul G. Cuddy	898
Section 10	Respiratory Drugs, Nickole N. Henyan	909
Chapter 57	Antiasthmatics, Laura L. Sanders	909
Chapter 58	Antihistamines, Laura L. Sanders	943
Chapter 59	Inhaled Corticosteroids, Laura L. Sanders	959
Chapter 60	Cough and Cold, Laura L. Sanders	973
PART II	CLINICAL INFORMATION	979
	Principal Editor: Kelly M. Smith	
Section 1	Drug-Induced Diseases	981
Chapter 61	Drug-Induced Blood Dyscrasias, Stephanie D. Sutphin	981
Chapter 62	Drug-Induced Hepatotoxicity, Trenika R. Mitchell	994
Chapter 63	Drug-Induced Nephrotoxicity, William R. Vincent III	1003
Chapter 64	Drug-Induced Oculotoxicity, Melanie Mabins	1014
Chapter 65	Drug-Induced Ototoxicity, William R. Vincent III	1025
Chapter 66	Drug-Induced Pancreatitis, Trenika R. Mitchell	1031
Chapter 67	Drug-Induced Sexual Dysfunction, Melanie Mabins	1035
Chapter 68	Drug-Induced Skin Disorders, Katherine D. Mieux	1044
Section 2	Drug Use in Special Populations	1051
Chapter 69	Drugs and Pregnancy, Kristina E. Ward	1051
Chapter 70	Drugs and Breast-Feeding, Philip O. Anderson	1080
Chapter 71	Pediatric Drug Therapy, William E. Murray	1111

Chapter 72	Geriatric Drug Therapy, <i>Emily R. Hajjar</i>	1116
Chapter 73	Renal Disease, <i>Gary R. Matzke, William E. Dager, and Brett H. Heintz</i>	1123
Chapter 74	Dialysis of Drugs, <i>Gary R. Matzke, William E. Dager, and Brett H. Heintz</i>	1132
Section 3	Immunization, <i>Andrea L. McKeever and Heather F. DeBellis</i>	1141
Section 4	Medical Emergencies: Anaphylaxis, Cardiac Arrest, Poisoning, Status Epilepticus	1191
Chapter 75	Anaphylaxis, <i>Frank Romanelli</i>	1191
Chapter 76	Cardiac Arrest, <i>Heather M. Schumann and Krysta A. Zack</i> ...	1193
Chapter 77	Poisoning, <i>F. Lee Cantrell</i>	1203
Chapter 78	Status Epilepticus, <i>April D. Miller</i>	1207
Section 5	Drug Interactions and Interferences	1211
Chapter 79	Cytochrome P450 Enzyme Interactions, <i>John R. Horn</i>	1211
Chapter 80	Drug-Induced Discoloration of Feces and Urine, <i>Annette T. McFarland and Amy Sutton Peak</i>	1216
Section 6	Nutrition Support, <i>Phil Ayers</i>	1223
PART III	APPENDICES	1237
	Principal Editor: Kelly M. Smith	
Appendix 1	Conversion Factors, <i>Kelly M. Smith</i>	1239
Appendix 2	Anthropometrics, <i>Kelly M. Smith</i>	1243
Appendix 3	Laboratory Indices: Blood, Serum, Plasma Chemistry; Urine, Renal Function Tests; Hematology, <i>Kelly M. Smith</i> ...	1247
Appendix 4	Drug-Laboratory Test Interferences, <i>Linda Sobeski Farho</i>	1252
Appendix 5	Pharmacokinetic Equations, <i>Gary Theilman</i>	1265
<i>Index</i>		1271

How to Use This Book

Part I of this book is organized around 10 major drug categories, which have been subdivided into common therapeutic groups. Within these therapeutic groups, drug information is alphabetically presented in three formats: **Monographs**, **Minimonographs**, and **Comparison Charts**. Monographs and Comparison Charts are *grouped together* to ensure that related drugs are easy to *compare* and *contrast*. Charts are located after the monographs to which they relate. Drug antagonists are grouped together with agonists to simplify organization and accessibility.

Monographs are used for drugs of major importance and prototype agents.

Minimonographs are used for drugs similar to prototype drugs, those of lesser importance within a therapeutic class, and promising investigational agents. Minimonographs contain only selected subheadings of information rather than all subheadings contained in the full monographs.

Comparison Charts are used to present clinically useful information on members of the same pharmacologic class and different drugs with a similar therapeutic use, as well as to present clinically relevant information on certain other topics.

The preferred method to gain access to complete information on a *particular brand* or *generic drug* is to use the index at the end of the book. The index may also direct the user to *other pertinent information* on the drug.

MONOGRAPH FORMAT

CLASS INSTRUCTIONS

This is an optional heading at the beginning of each drug class. It consists of patient instructions that apply to more than one of the drug monographs in this subcategory. If all drugs are not identical in their instructions, only the common information is found here. The Patient Instructions section of each monograph that is affected states, “*See Class Instructions*” as the opening phrase.

GENERIC DRUG NAME

Brand Name(s)

The *nonproprietary (generic)* name is listed on the left, followed by common brand names listed on the right. Brand-name products listed are not necessarily superior or preferable to other brand-name or generic products; “Various” indicates the availability of additional brand and/or generic products.

Pharmacology. A description of the chemistry, major mechanisms of action, and human pharmacology of the drug in clinical application.

Administration and Adult Dosage. Route of administration, indications, and usual adult dosage range are given for the most common labeled uses. Dosages correspond

to those in the product labeling or in standard reference sources. "Dose" refers to a single administration and "dosage" to a cumulative amount (e.g., daily dosage).

Special Populations. Dosages in patient populations other than the typical adult are listed:

Pediatric Dosage (given by age or weight range)

Geriatric Dosage (given by age range)

Other Conditions (renal failure, hepatic disease, obesity, etc.)

Dosage Forms. The most commonly used dosage forms and available strengths are listed, as well as popular combination product dosage forms. Prediluted IV piggy-back or large-volume parenteral containers are not listed unless this is the only commercially available product.

Patient Instructions. Key information that should be provided to the patient when prescribing or dispensing medication is presented. When introductions apply to an entire drug category, see "Class Instructions" at the beginning of that subcategory.

Missed Doses. What the patient should do if one or more doses are missed.

Pharmacokinetics. Data are presented as the mean \pm the standard deviation. Occasionally the standard error of the mean (SE) is the only information available on variability, and it is identified as such.

Onset and Duration (time course of the pharmacologic or therapeutic effect)

Serum Levels (therapeutic and toxic plasma concentrations are given)

Fate (The course of the drug in the body is traced. Pharmacokinetic parameters are generally provided as total body weight normalized values. The volume of distribution is either a V_d in a one-compartment system or V_c and $V_{d\beta}$ or V_{dss} in a two-compartment system.)

$t_{1/2}$ (terminal half-life is presented)

Adverse Reactions. Reactions known to be dose related are usually given first, then other reactions in decreasing order of frequency. Reaction frequency is classified into three ranges. However, percentages of reactions may be provided for reactions that occur more frequently than 1%.

frequent ($>1/100$ patients)

occasional ($1/100$ to $1/10,000$ patients)

rare ($<1/10,000$ patients)

Contraindications. Those listed in product labeling are given. "Hypersensitivity" is not listed as a contraindication because it is understood that patients should usually not be given a drug to which they are allergic or hypersensitive—exceptions are noted.

Precautions. Warnings for use of the drug in certain disease states and/or patient populations, together with any cross-sensitivity with other drugs. Part II, Section 2, "Drug Use in Special Populations," should be consulted for more information, particularly regarding pregnancy and breastfeeding.

Drug Interactions. The most important drug interactions are listed.

Parameters to Monitor. Important clinical signs and/or laboratory tests to monitor to ensure safe and effective use are presented. The frequency of monitoring may also be given; however, for many drugs the optimal frequency has not been determined.

Notes. Distinguishing characteristics, therapeutic usefulness, or relative efficacy of the drug are presented, as well as unique or noteworthy physicochemical properties, handling, storage, or relative cost.

Drug Monographs

Principal Editors: David M. Nichols and Rickelle M. Hargrave

Section 1: Anesthetic and Anti-Parasitic Drugs 3

Section 2: Antineoplastic Drugs 15

Section 3: Anti-Infectives, Chemoprotectors, and
Immunosuppressants 209

Section 4: Cardiovascular Drugs 269

Section 5: Central Nervous System 313

Section 6: Gastrointestinal Drugs 329

Section 7: Hematologic Drugs 429

Section 8: Hormonal Drugs 489

Section 9: Insect and Fungicides 549

Section 10: Miscellaneous Drugs 599